Article

Monotherapy after initial diagnosis helps patient compliance

Baltimore-Patients who received latanoprost (Xalatan, Pharmacia Corp., Peapack, NJ) to treat glaucoma were more likely to adhere to their regimens and less likely to discontinue their medications compared with patients who are prescribed beta-blockers, carbonic anhydrase inhibitors, or brimonidine, according to Gail Schwartz, MD, and her colleagues.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.